title: Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema.
abstract: We sought to assess whether the effects of mesenchymal stromal cells (MSC) on lung inflammation and remodeling in experimental emphysema would differ according to MSC source and administration route. Emphysema was induced in C57BL/6 mice by intratracheal (IT) administration of porcine pancreatic elastase (0.1 UI) weekly for 1 month. After the last elastase instillation, saline or MSCs (1×105), isolated from either mouse bone marrow (BM), adipose tissue (AD) or lung tissue (L), were administered intravenously (IV) or IT. After 1 week, mice were euthanized. Regardless of administration route, MSCs from each source yielded: 1) decreased mean linear intercept, neutrophil infiltration, and cell apoptosis; 2) increased elastic fiber content; 3) reduced alveolar epithelial and endothelial cell damage; and 4) decreased keratinocyte-derived chemokine (KC, a mouse analog of interleukin-8) and transforming growth factor-β levels in lung tissue. In contrast with IV, IT MSC administration further reduced alveolar hyperinflation (BM-MSC) and collagen fiber content (BM-MSC and L-MSC). Intravenous administration of BM- and AD-MSCs reduced the number of M1 macrophages and pulmonary hypertension on echocardiography, while increasing vascular endothelial growth factor. Only BM-MSCs (IV > IT) increased the number of M2 macrophages. In conclusion, different MSC sources and administration routes variably reduced elastase-induced lung damage, but IV administration of BM-MSCs resulted in better cardiovascular function and change of the macrophage phenotype from M1 to M2.
authors.forename: Mariana A
authors.initials: MA
authors.lastname: Antunes
authors.forename: Soraia C
authors.initials: SC
authors.lastname: Abreu
authors.forename: Fernanda F
authors.initials: FF
authors.lastname: Cruz
authors.forename: Ana Clara
authors.initials: AC
authors.lastname: Teixeira
authors.forename: Miquéias
authors.initials: M
authors.lastname: Lopes-Pacheco
authors.forename: Elga
authors.initials: E
authors.lastname: Bandeira
authors.forename: Priscilla C
authors.initials: PC
authors.lastname: Olsen
authors.forename: Bruno L
authors.initials: BL
authors.lastname: Diaz
authors.forename: Christina M
authors.initials: CM
authors.lastname: Takyia
authors.forename: Isalira P R G
authors.initials: IP
authors.lastname: Freitas
authors.forename: Nazareth N
authors.initials: NN
authors.lastname: Rocha
authors.forename: Vera L
authors.initials: VL
authors.lastname: Capelozzi
authors.forename: Débora G
authors.initials: DG
authors.lastname: Xisto
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Weiss
authors.forename: Marcelo M
authors.initials: MM
authors.lastname: Morales
authors.forename: Patricia R M
authors.initials: PR
authors.lastname: Rocco
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000502:physiology*; D002478:Cells, Cultured; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D011656:Pulmonary Emphysema / Q000473:pathology* / Q000628:therapy*; D011897:Random Allocation; D016896:Treatment Outcome